PMID- 31599972 OWN - NLM STAT- MEDLINE DCOM- 20200608 LR - 20200608 IS - 1537-2995 (Electronic) IS - 0041-1132 (Linking) VI - 59 IP - 11 DP - 2019 Nov TI - RBC and platelet transfusion support in the first 30 and 100 days after haploidentical hematopoietic stem cell transplantation. PG - 3371-3385 LID - 10.1111/trf.15531 [doi] AB - BACKGROUND: The volume of haploidentical hematopoietic stem cell transplant (haplo-HSCT) has increased dramatically in recent years. However, the associated higher risk of delayed engraftment may increase patient transfusion requirements. STUDY DESIGN AND METHODS: The post-HSCT RBC and platelet transfusions of 195 haplo-HSCT recipients were evaluated. Patient and transplant-related factors potentially impacting the number of products transfused and time to transfusion independence were assessed. RESULTS: Nearly all (98.4%) patients were transfused in the first 30 days, and 59.2% were transfused between days 31 and 100. Among the transfused patients, medians of 5 units (interquartile range [IQR] = 3-8) of RBCs and 11 units (6-20) platelets were given in the first 30 days, and medians of 3 units (IQR = 1-7) of RBCs and 6 units (2-18) of platelets were transfused between days 31 and 100. Median times for achieving RBC and platelet transfusion independence were 34 (95% CI: 28-40) and 25 (95% CI: 23-27) days, respectively. Multivariable analyses showed that RBC transfusions in the 10 days before HSCT were associated with significantly increased and sustained RBC and platelet transfusion requirements. Major ABO incompatibility led to increased RBC transfusions. Advanced disease was associated with increased transfusions during the first 30 days, whereas GVHD increased platelet transfusions between days 31 and 100. Effects of age, sex, CD34+ cell dose, stem cell source, and conditioning regimen were limited or insignificant. CONCLUSIONS: This study for the first time provided quantitative transfusion data on a large cohort of haplo-HSCT recipients and identified factors predictive of increased transfusions. CI - (c) 2019 AABB. FAU - Yuan, Shan AU - Yuan S AUID- ORCID: 0000-0002-9424-1790 AD - Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California. FAU - Yang, Dongyun AU - Yang D AD - Department of Computational and Quantitative Medicine, City of Hope National Medical Center, Duarte, California. FAU - Nakamura, Ryotaro AU - Nakamura R AD - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California. FAU - Zhuang, Lefan AU - Zhuang L AD - Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California. FAU - Al Malki, Monzr M AU - Al Malki MM AD - Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California. FAU - Wang, Shirong AU - Wang S AD - Division of Transfusion Medicine, Department of Pathology, City of Hope National Medical Center, Duarte, California. LA - eng PT - Journal Article DEP - 20191010 PL - United States TA - Transfusion JT - Transfusion JID - 0417360 RN - 0 (ABO Blood-Group System) SB - IM MH - ABO Blood-Group System/immunology MH - Adolescent MH - Adult MH - Aged MH - Blood Group Incompatibility MH - *Erythrocyte Transfusion MH - Female MH - Graft vs Host Disease/epidemiology/prevention & control MH - *Hematopoietic Stem Cell Transplantation/adverse effects/mortality MH - Humans MH - Male MH - Middle Aged MH - *Platelet Transfusion MH - Time Factors MH - *Transplantation, Haploidentical MH - Young Adult EDAT- 2019/10/11 06:00 MHDA- 2020/06/09 06:00 CRDT- 2019/10/11 06:00 PHST- 2019/07/12 00:00 [received] PHST- 2019/08/30 00:00 [revised] PHST- 2019/08/30 00:00 [accepted] PHST- 2019/10/11 06:00 [pubmed] PHST- 2020/06/09 06:00 [medline] PHST- 2019/10/11 06:00 [entrez] AID - 10.1111/trf.15531 [doi] PST - ppublish SO - Transfusion. 2019 Nov;59(11):3371-3385. doi: 10.1111/trf.15531. Epub 2019 Oct 10.